

### AMENDMENTS TO THE SPECIFICATION

**Please replace the paragraph beginning on page 4, line 24, with the following rewritten paragraph:**

— Fig. 1 is a diagram depicting a portion of the amino acid sequence of human E-cadherin (SWISS-PROT ACCESSION NO. P12830) (SEQ ID NO:19) indicating the N-termini of E-Cad/CTF1 and E-Cad/CTF2. Arrows identify the cleavage sites of MMP and PS1/ $\gamma$ -secretase-like cleavage. The sequence mediating E-cadherin-PS1 binding identified by Baki et al. (2001) Proc. Natl. Acad. Sci. USA 98:2381-2386 is underlined. EC1-5 denote the extracellular E-cadherin repeats. TM denotes the transmembrane domain. —

**Please replace the paragraph beginning on page 12, line 24 with the following rewritten paragraph:**

— In a preferred embodiment, the ICD  $\epsilon$ -cleavage product that is measured is N-Cad/CTF2 or E-Cad/CTF2 or VE-Cad/CTF2. E-Cad/CTF2, depicted in Figure 1 (SEQ ID NO:19), comprises amino acids 732-882 of human E-cadherin (SWISS-PROT P12830). N-Cad/CTF2 comprises amino acids 747-906 of human N-cadherin (SWISS-PROT P19022). VE-Cad/CTF2 comprises amino acids 621-784 of VE-cadherin (SWISS-PROT P33151). The ICD cleavage products of other cadherins are defined as the C-terminal portion of cadherin generated by the  $\gamma$ -secretase-like  $\epsilon$ -cleavage. The production of the ICD  $\epsilon$ -cleavage product may be assessed in cells obtained from tissue of a patient, including non-neural tissue such as skin, or from cell cultures established from a patient. —

**Please replace the previously submitted text entitled “SEQUENCE LISTING” and insert the enclosed 4-page text entitled “SUBSTITUTE SEQUENCE LISTING” immediately preceding the claims.**